Report From J-PULSE Multicenter Registry of Patients With Shock-Resistant Out-of-Hospital Cardiac Arrest Treated With Nifekalant Hydrochloride
Authors:
- The J-PULSE InvestigatorsTIThe J-PULSE Investigators
- 1 January 2010
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 74 (11) , 2308-2313
Abstract
Nifekalant hydrochloride (NIF) is an intravenous class-III antiarrhythmic agent that purely blocks the K(+)-channel without inhibiting β-adrenergic receptors. The present study was designed to investigate the feasibility of NIF as a life-saving therapy for out-of-hospital ventricular fibrillation (VF). The Japanese Population-based Utstein-style study with basic and advanced Life Support Education study was a multi-center registry study with 4 participating institutes located at the northern urban area of Osaka, Japan. Eligible patients were those treated with NIF because of out-of-hospital VF refractory to 3 or more precordial shocks and intravenous epinephrine. Between February 2006 and February 2007, 17 patients were enrolled for the study. The time from a call for emergency medical service to the first shock was 12(6-26)min. The time from the first shock to the NIF administration was 25.5(9-264)min and the usage dose of NIF was 25(15-210)mg. When excluding 3 patients in whom percutaneous extracorporeal membrane oxygenation was applied before NIF administration, the rate of return of spontaneous circulation was 86% and the rate of admission alive to the hospital was 79%. One patient developed torsade de pointes. Intravenous administration of NIF seems to be feasible as a potential therapy for advanced cardiac life-support in patients with out-of-hospital VF, and therefore further study is warranted.Keywords
This publication has 22 references indexed in Scilit:
- Essential Features of Designating Out-of-Hospital Cardiac Arrest as a Reportable EventCirculation, 2008
- Prevention of Life-Threatening Ventricular Tachyarrhythmia by a Novel and Pure Class-III Agent, Nifekalant HydrochlorideJournal of Cardiovascular Pharmacology, 2006
- The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogsJACC, 2002
- Amiodarone as Compared with Lidocaine for Shock-Resistant Ventricular FibrillationNew England Journal of Medicine, 2002
- Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug.Folia Pharmacologica Japonica, 2002
- Acute Electropharmacological Effects of Intravenously Administered Amiodarone Assessed in the In Vivo Canine ModelThe Japanese Journal of Pharmacology, 2001
- Amiodarone for Resuscitation after Out-of-Hospital Cardiac Arrest Due to Ventricular FibrillationNew England Journal of Medicine, 1999
- Can a Class III Antiarrhythmic Drug Improve Electrical Defibrillation Efficacy During Ventricular Fibrillation?JACC, 1997
- Cellular electrophysiological effects of MS‐551, a new class III antiarrhythmic agentDrug Development Research, 1995
- Effects of MS-551, a New Class III Antiarrhythmic Drug, on Programmed Stimulation-Induced Ventricular Arrhythmias, Electrophysiology, and Hemodynamics in a Canine Myocardial Infarction ModelJournal of Cardiovascular Pharmacology, 1994